Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
Spinal Cord Injury ll: Pathophysiology01:14

Spinal Cord Injury ll: Pathophysiology

25
Spinal cord injury progresses through two interconnected phases: primary injury and secondary injury.Primary InjuryPrimary injury happens at the moment of trauma and involves immediate mechanical damage to the spinal cord.Compression happens when broken vertebrae, herniated discs, or accumulating blood (such as a hematoma) press directly against the spinal cord, distorting its normal shape and function. In cases of contusion, the cord is bruised by a blunt force (like penetrating injuries or...
25

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucose-dependent spatial and temporal modulation of oligodendrocyte progenitor cell proliferation via ACLY-regulated histone acetylation.

Nature neuroscience·2026
Same author

Telomeric RNA and HP1α form interfacial clusters that stabilize HP1α-DNA condensates.

Communications biology·2025
Same author

The Histone Methyltransferases EHMT1 and EHMT2 Repress the Expression of Genes Related to Excitability and Cell Death in Oligodendrocyte Progenitors.

Glia·2025
Same author

Neuroprotective effect of neuron-specific deletion of the C16 ceramide synthetic enzymes in an animal model of multiple sclerosis.

Glia·2024
Same author

Developmental maturation and regional heterogeneity but no sexual dimorphism of the murine CNS myelin proteome.

Glia·2024
Same author

PDGF-BB overexpression in p53 null oligodendrocyte progenitors increases H3K27me3 and induces transcriptional changes which favor proliferation.

Neoplasia (New York, N.Y.)·2024

Related Experiment Video

Updated: May 4, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

9.9K

Promoting return of function in multiple sclerosis: An integrated approach.

Mar Gacias1, Patrizia Casaccia2

  • 1Department of Neuroscience, Friedman Brain Institute, United States.

Multiple Sclerosis and Related Disorders
|December 24, 2013
PubMed
Summary
This summary is machine-generated.

Multiple sclerosis (MS) treatments effectively reduce relapses but not progressive neurological damage. Future therapies must address neuroprotection and remyelination for holistic MS management, considering genetic and lifestyle factors.

Keywords:
Axonal damageEpigeneticsMultiple sclerosisNeurodegenerationRepairTherapymyelin

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

29.7K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K

Related Experiment Videos

Last Updated: May 4, 2026

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

9.9K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

29.7K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Multiple sclerosis (MS) involves inflammatory demyelination, axonal damage, and brain atrophy.
  • Current disease-modifying agents manage relapses but fail to halt progressive disability.
  • Persistent neuronal damage necessitates strategies beyond immunomodulation.

Purpose of the Study:

  • To emphasize the need for therapeutic strategies addressing axonal protection and remyelination in MS.
  • To advocate for a holistic approach to MS treatment, integrating genetic and epigenetic factors.
  • To highlight the influence of lifestyle and demographics on therapeutic responsiveness.

Main Methods:

  • Review of current understanding of MS pathology and treatment limitations.
  • Analysis of factors influencing therapeutic outcomes in multiple sclerosis.
  • Discussion of the interplay between genetics, epigenetics, and lifestyle in MS.

Main Results:

  • Existing MS therapies primarily target relapse reduction.
  • Progressive neurodegeneration and irreversible disability persist despite current treatments.
  • Variability in treatment response is linked to genetic, epigenetic, and lifestyle factors.

Conclusions:

  • Effective MS management requires a dual approach: immunomodulation plus neuroprotection and remyelination.
  • A personalized, holistic strategy considering individual variability is crucial for optimal MS care.
  • Understanding the interplay of genetics, epigenome, and lifestyle is key to improving MS treatment outcomes.